UK Govt Launches Biotech "Crusade"

23 June 1996

The UK government has launched a "Crusade for Biotechnology," with the aim of boosting the country's place at the forefront of global biotechnology. The initiative consists of a package of measures to stimulate the industrial exploitation of biotechnology and coordinate government activities.

One of the UK's leading biotechnology companies, British Biotech, applauded the initiative. The firm's chairman, Keith McCullagh, who is also chairman of the UK BioIndustry Association, commented: "to achieve success, bioscience companies need scientific entrepreneurship and venture capital backing at the start-up phase, sustained investment through the development phase and a climate of rational science-based regulation as their products reach market launch. The government's initiative in setting out the framework for the achievement of all three of these objectives is appreciated by the whole industry and warmly welcomed by us."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight